Financial Daily from THE HINDU group of publications
Monday, Jul 04, 2005

News
Features
Stocks
Port Info
Archives
Google

Group Sites

Corporate - Announcements


Aurobindo Pharma gets US approval for Efavirenz

Our Bureau

Hyderabad , July 3

AUROBINDO Pharma Ltd on Sunday announced that it has received approval from the US Food and Drug Administration for Efavirenz tablets, 600 mg, which it claims is the first generic approval given to it ahead of the rest of the industry.

Efavirenz is a key anti-retro viral (ARV) for AIDS therapy. This is the third ARV approval with the other products being Neviraphine and Lumivudine. Efavirenz represents a significant opportunity in Africa for Aurobindo under the PEPFAR (the President's Emergency Plan for AIDS relief) programme. PEPFAR is a five-year programme backed by the US Government to fight the HIV/AIDS pandemic.

According to a statement from Aurobindo, Efavirenz is internationally referred to as Susitva, which is manufactured by Bristol Myers Squibb Co.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page


Stories in this Section
IOC's Gujarat refinery resumes operations


Aurobindo Pharma gets US approval for Efavirenz
Refinery capacity to be doubled
Ignorance of law: Is it feigned or real?
CLB orders Govt to appoint 2 directors on Morepen board
`Acquisitions: Indian cos outperform foreign firms'
Local opposition puts Chemfab desalination project in hot water
Madras Engg plans auto slack adjuster unit in SEZ
Ion Exchange sets up desalination plant in Nagapattinam
Ashok Leyland bullish on multi-axle vehicle segment
Swaraj Mazda to roll out medium, heavy commercial vehicles
Bentley launches Continental Flying Spur


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line